| David A. Scheinberg | |
| Profession: | Physician-scientist |
| Specialism: | Leukemia |
| Education: | Cornell University BAJohns Hopkins University School of Medicine MD, PhD |
| Work Institutions: | Memorial Sloan Kettering Cancer Center Weill Cornell Medicine |
David A. Scheinberg is an American physician, scientist, drug developer, and entrepreneur, who is currently Vincent Astor Chair, and Chairman of the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center (MSK).[1] He is a pioneer and inventor of targeted alpha particle therapies and alpha particle generators for use in patients with cancer.[2] [3]
Scheinberg received a BA from Cornell University and an MD, PhD from Johns Hopkins University School of Medicine. He is a professor of pharmacology and co-chair of the pharmacology graduate program at Weill Cornell Graduate School of Medical Sciences and a professor at the Gerstner Sloan Kettering Graduate School. He also founded and chairs the Experimental Therapeutics Center and formerly the Nanotechnology Center at MSK. He founded and is a Director of the Tri-Institutional Therapeutics Discovery Institute of MSK, Weill Cornell Medicine, and Rockefeller Universities.
In 2013 Nature Biotechnology recognized him as one of the top 20 Translational Scientists in the world.[4] Scheinberg has published more than 300 papers, chapters, or books and has more than 30 patents.
His laboratory studies cancer immunology, cellular engineering, cancer vaccines, T cell receptor mimic antibodies, and targeted nano-machines.